Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT07156253 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumor
Ovarian Cancer
Breast Cancer
BRCA 1 /2 and / or HRD
Advanced Solid Tumors

Interventions

DRUG: SYN818 and Olaparib will be administered

Sponsor

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd